A vaccine against norovirus, the dreaded “winter vomiting bug”, could be closer than you think: early clinical trials have ...

Researchers have identified antibodies that could lead to a broadly protective norovirus vaccine and new treatment options.

Identifying antibodies for 75% of norovirus outbreaks, University researchers took a step forward in creating a vaccine for ...

A new orally administered norovirus vaccine tablet has demonstrated promising safety and immunogenicity in older adults.

Here’s what happened after RFK Jr. paused Peninsula company's half-billion-dollar vaccine contract. Spoiler alert: It wasn’t ...

4 Sidney 2012 norovirus variant and a double-stranded RNA adjuvant. The vaccine back-boosted broad GII.4 and cross-GII blockade clonotypes. In one participant, four broadly neutralizing antibodies ...

Adrienne Tomusiak, whose three children under three are all in daycare, has seen it all this winter for sickness, from ...

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as ...

Thanks, Steve. Vaxart continues to make important advancements with our promising norovirus vaccine candidate in clinical development. Earlier this month, we initiated a Phase 1 clinical trial ...

The company has initiated a Phase 1 trial for their second-generation oral Norovirus vaccine, which shows potential for improved potency over the first-generation constructs. Vaxart Inc (NASDAQ ...

Sequoia Financial Advisors LLC increased its stake in shares of Vaxart, Inc. (NASDAQ:VXRT – Free Report) by 140.9% during the ...

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID ...